• FirefoxUpgrade to the new Firefox »
  •  Dow Down 1.13% Nasdaq Down 0.93%

    ArQule Inc. (ARQL)

    -NasdaqGM
    1.14 0.02(1.79%) Jan 28, 4:00PM EST
    Add to Portfolio
    Prev Close:1.12
    Open:1.13
    Bid:N/A
    Ask:1.50 x 300
    1y Target Est:2.42
    Beta:1.94
    Earnings Date:Mar 3 - Mar 9 (Est.)
    Day's Range:1.09 - 1.14
    52wk Range:1.04 - 2.37
    Volume:48,400
    Avg Vol (3m):385,690
    Market Cap:71.56M
    P/E (ttm):N/A
    EPS (ttm):-0.41
    Div & Yield:N/A (N/A)
    Quotes delayed, except where indicated otherwise. Currency in USD.

    Comparison

    Symbol% ChgMkt Cap
    ARQLUp 1.79%71.56M
    ARRY976.53M

    Key Statistics

    Forward P/E (1 yr):N/A
    P/S (ttm):6.69
    Ex-Dividend Date:N/A

    Analysts

    Annual EPS Est (Dec-14) :-0.43
    Quarterly EPS Est (Dec-14) :-0.13
    Mean Recommendation*:2.6
    PEG Ratio (5 yr expected):-0.52

    * (Strong Buy) 1.0 - 5.0 (Sell)

    Analyst Opinion | Estimates

    Business Summary

    ArQule, Inc., a clinical-stage biotechnology company, researches and develops cancer therapeutics. Its lead product candidate tivantinib is an inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase 3 clinical... View More
    Your browser doesn't support canvas
    SETTINGS
    Scrolling
    Speed
    Display
    Price
    Submit Feedback